Cargando…

Serum ATX as a novel biomarker for breast cancer

Recent accumulating evidence indicates the biological actions of Autotaxin-Lysophosphatidic acid (ATX-LPA) signaling axis in malignant tumors. However, the role of Autotaxin-Lysophosphatidic acid signaling axis in breast cancer has not been reported. The present study aims to examine the alterations...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Yingbo, Yu, Yang, He, Yaning, Chen, Qi, Liu, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456097/
https://www.ncbi.nlm.nih.gov/pubmed/30921203
http://dx.doi.org/10.1097/MD.0000000000014973
_version_ 1783409704907571200
author Shao, Yingbo
Yu, Yang
He, Yaning
Chen, Qi
Liu, Hui
author_facet Shao, Yingbo
Yu, Yang
He, Yaning
Chen, Qi
Liu, Hui
author_sort Shao, Yingbo
collection PubMed
description Recent accumulating evidence indicates the biological actions of Autotaxin-Lysophosphatidic acid (ATX-LPA) signaling axis in malignant tumors. However, the role of Autotaxin-Lysophosphatidic acid signaling axis in breast cancer has not been reported. The present study aims to examine the alterations of serum autotaxin in breast cancer and discuss whether serum autotaxin could be useful as a novel parameter of breast cancer. Serum autotaxin antigen was measured in 112 patients with breast cancer and 50 healthy volunteers by ELISA. The association of serum autotaxin antigen levels with clinicopathological parameters and outcomes of breast cancer was analyzed. Serum autotaxin antigen was significantly higher in breast cancer patients than healthy volunteers (291.32 ± 38.02 ng/ml vs 254.04 ± 21.03 ng/ml, respectively; P < .0001). Serum autotaxin measurement successfully discriminated breast cancer patients from normal and healthy controls (AUC = 0.798, 95% CI: 0.732–0.864) with an optimal cut-off value of 267.34 ng/ml (sensitivity = 0.741, specificity = 0.800). Increased serum autotaxin was associated with breast cancer nodal status (P = .007), Tumor-Node- Metastasis (TNM) stage (P = .009) and Ki-67 index (P = .004). Univariate and multivariate Cox regression analysis revealed that elevated serum autotaxin showed an independent prognostic value for poor Disease-free survival. Our present study confirmed the elevation, potential diagnostic, and independent prognostic value of serum autotaxin for breast cancer. Serum autotaxin could serve as a reliable novel biomarker for breast cancer.
format Online
Article
Text
id pubmed-6456097
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-64560972019-05-29 Serum ATX as a novel biomarker for breast cancer Shao, Yingbo Yu, Yang He, Yaning Chen, Qi Liu, Hui Medicine (Baltimore) Research Article Recent accumulating evidence indicates the biological actions of Autotaxin-Lysophosphatidic acid (ATX-LPA) signaling axis in malignant tumors. However, the role of Autotaxin-Lysophosphatidic acid signaling axis in breast cancer has not been reported. The present study aims to examine the alterations of serum autotaxin in breast cancer and discuss whether serum autotaxin could be useful as a novel parameter of breast cancer. Serum autotaxin antigen was measured in 112 patients with breast cancer and 50 healthy volunteers by ELISA. The association of serum autotaxin antigen levels with clinicopathological parameters and outcomes of breast cancer was analyzed. Serum autotaxin antigen was significantly higher in breast cancer patients than healthy volunteers (291.32 ± 38.02 ng/ml vs 254.04 ± 21.03 ng/ml, respectively; P < .0001). Serum autotaxin measurement successfully discriminated breast cancer patients from normal and healthy controls (AUC = 0.798, 95% CI: 0.732–0.864) with an optimal cut-off value of 267.34 ng/ml (sensitivity = 0.741, specificity = 0.800). Increased serum autotaxin was associated with breast cancer nodal status (P = .007), Tumor-Node- Metastasis (TNM) stage (P = .009) and Ki-67 index (P = .004). Univariate and multivariate Cox regression analysis revealed that elevated serum autotaxin showed an independent prognostic value for poor Disease-free survival. Our present study confirmed the elevation, potential diagnostic, and independent prognostic value of serum autotaxin for breast cancer. Serum autotaxin could serve as a reliable novel biomarker for breast cancer. Wolters Kluwer Health 2019-03-15 /pmc/articles/PMC6456097/ /pubmed/30921203 http://dx.doi.org/10.1097/MD.0000000000014973 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Research Article
Shao, Yingbo
Yu, Yang
He, Yaning
Chen, Qi
Liu, Hui
Serum ATX as a novel biomarker for breast cancer
title Serum ATX as a novel biomarker for breast cancer
title_full Serum ATX as a novel biomarker for breast cancer
title_fullStr Serum ATX as a novel biomarker for breast cancer
title_full_unstemmed Serum ATX as a novel biomarker for breast cancer
title_short Serum ATX as a novel biomarker for breast cancer
title_sort serum atx as a novel biomarker for breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456097/
https://www.ncbi.nlm.nih.gov/pubmed/30921203
http://dx.doi.org/10.1097/MD.0000000000014973
work_keys_str_mv AT shaoyingbo serumatxasanovelbiomarkerforbreastcancer
AT yuyang serumatxasanovelbiomarkerforbreastcancer
AT heyaning serumatxasanovelbiomarkerforbreastcancer
AT chenqi serumatxasanovelbiomarkerforbreastcancer
AT liuhui serumatxasanovelbiomarkerforbreastcancer